TGFB3 and systemic sclerosis: We have recently shown that isoform-selective inhibition of TGFβ3 may attenuate fibrosis without inducing excessive inflammation (63), and that isoform-selective TGFβ3 targeting is safe and well-tolerated in preclinical toxicology studies [PMID:40317127], representing a refined therapeutic approach that is currently under clinical investigation in SSc.